semaj83/ctmatch_classification huggingface dataset:
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Esophagus Cancer Biopsy proven Carcinoma of the oesophagus Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness. (It should be noted that, patients with mediastinal nodes and no more distant disease maybe suitable for radical treatment) Symptomatic patients with dysphagia scores of ≥ 1 i.e. able to eat only some solids (see Mellow Scale appendix 1) Performance status ECOG ≤ 2 Patients must begin treatment within 2 weeks of randomization Patient is at least 18 years old Adequate haematological function to undergo chemotherapy. Peripheral blood Neutrophils > 1.5 x 10^9/L Platelets > 100 x 10^9/L Adequate renal function, Creatinine  Previous mega-voltage external beam Radiotherapy or brachy-therapy delivered to the region of the chest Synchronous active malignancies Pregnant or lactating patients Patients unfit for any treatment component Tracheo-oesophageal fistula Stents in situ Previous chemotherapy for Oesophageal Cancer CT scan of thorax and abdomen more than 8 weeks prior to randomization Full Blood Count, Biochemistry (including creatinine) and creatinine clearance more than 2 weeks prior to randomization
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Esophagitis Patients aged 18-90 presenting with dysphagia or food impaction Ability to undergo esophagogastroduodenoscopy and biopsies No significant cardiopulmonary disease, or other contraindication to EGD  Contradiction to EGD and/or biopsies such as Boerhaave's syndrome, or history or bleeding disorder or elevated INR Inability to provide informed consent Esophageal varices
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Healthy Volunteers Non-pregnant, non-breastfeeding females years old Body mass index between 20 and 32 kg/m2 No alarm indicators on clinical assessment (weight loss of more than 7kg, bleeding, recent recurrent vomiting, progressive dysphagia) No history suggestive of small bowel obstruction
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Gastrointestinal Mucositis (Defined as Mucositis Involving the Mouth, Esophagus, or Small Intestine) years or older Ability to understand the protocol and willing to provide written informed consent Membership in one of the following sub-cohorts Histologically proven oral cavity or oropharyngeal cancers planned to receive a full cycle of daily single fraction radiation therapy (with or without boost) or IMRT +/ chemotherapy Histologically proven laryngeal or hypopharyngeal cancers planned to receive a full cycle of daily single fraction radiation (with or without boost) +/ chemotherapy Histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of +/ Avastin or Erbitux.1 cycle defined as 2 doses of Histologically proven adenocarcinoma of the colon or rectum planned to receive a minimum of 2 cycles of +/
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Cancer Lung Cancer Patients with either: a) histologically proven stage I, II, IIIa NSCLC who have undergone a complete surgical resection of the primary tumor OR b) stage I or II HNSCC who have undergone definitive local treatment (surgery or radiation therapy) HNSCC patients:Definitive local treatment </= 12 months prior to trial enrollment. NSCLC patients: Surgery </= 12 months prior to trial enrollment No evidence residual cancer Age > = 18 years Performance status of 0 (Zubrod) Patients must have no contraindications for undergoing bronchoscopy Patients must have no active pulmonary infections Participants must have the following blood levels: total granulocyte count >1500; platelet count > 100,000; total bilirubin < = 1.5 mg. %; and creatinine < = 1.5 mg % Participants must complete the pretreatment evaluation and must consent to bronchoscopy and to endobronchial biopsy for biomarker studies  History of radiation therapy to the chest. For those patients with head and neck cancer who received radiation, no more than 10% of the lung volume (apices) may be included History of systemic chemotherapy. Exception: NSCLC patients may have had up to 4 cycles of platinum-based doublet therapy Pregnant or breast-feeding (a negative pregnancy test within 72 hours of enrollment for women with child-bearing potential is required) Participants with active pulmonary infections or recent history of pulmonary infection (within one month) Participants with acute intercurrent illness Participants requiring chronic ongoing treatment with NSAIDs except aspirin Participants with history of stroke, uncontrolled hypertension, and/or uncontrolled angina pectoris Patients may not take high dose antioxidants (vitamins E or C) during the study period. "High dose" will be determined by the study investigators Patients may not take high dose synthetic or natural Vitamin A derivatives (> 10,000 IU per day). "High dose" is defined as anything greater than a once-daily multivitamin. Any additional supplementation will be evaluated at the discretion of the treating physician History of biologic therapy
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Cancer years or older Diagnosed with head and neck cancer including the lip, oral cavity, salivary glands, paranasal sinuses, oropharynx, nasopharynx, hypopharynx, larynx, and thyroid All histological types of cancer All tumour stages according to American Joint Committee for Cancer (AJCC) Staging All forms of RT including standard or investigational and/or concurrent standard or investigational chemotherapy for head and neck cancers Alert and mentally competent English speaking  Unwilling to participate
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pharyngitis The patient must have a diagnosis of pharyngitis with objective findings of tonsillo-pharyngitis The patient is willing to take "nothing by mouth" including inhaled treatments except trial medication during the two hours while at the site and following trial drug administration (e.g. not smoking, food, drink, candy, lozenges, chewing gum). The patient will be allowed food and drink between hours 2 and 24, but no other oral or inhaled treatments such as smoking, lozenges, chewing gum. After the two hour assessment, the patients will be allowed food and drink within one half-hour following any hourly evaluations sore throat  The patient has used any analgesic/antipyretic within 1 dosing interval preceding administration of the first dose of trial medication The patient anticipates using any inhaled therapy including beta-agonists (e.g., ventolin) during the 24 hour trial period and, if used, has only used inhaled therapy on an intermittent basis in the week prior to the screening visit
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Ovarian Cancer Primary Peritoneal Cavity Cancer Age ≥ 18 years Must have persistent, recurrent or progressive ovarian cancer or primary peritoneal cancer after prior treatment with platinum and taxol compounds. Histologic confirmation of the original primary tumor is required. Prior bilateral oophorectomy is required Patients with the following histologic epithelial cell types are eligible: Serous adenocarcinoma, endometroid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma NOS The following laboratory values obtained ≤7 days prior to registration ANC ≥ 1500/μL PLT ≥ 100,000/μL Total bilirubin ≤ upper normal limit AST ≤ 2 x ULN Creatinine ≤ 1.5 x ULN Hgb ≥ 9.0 g/dL  Epithelial tumors of low malignant potential, stromal tumors, and germ cell tumors of the ovary Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy. Subjects will be excluded if this is their first relapse and they have recurred >6 mo from completion of primary (adjuvant) chemotherapy ECOG performance status (PS) 3 or 4 Active infection ≤5 days prior to registration History of tuberculosis or history of PPD positivity History of other malignancy ≤5 years except for non-melanoma skin cancer or carcinoma in situ of the cervix Any of the following prior therapies Chemotherapy ≤ 3 weeks prior to study entry Immunotherapy ≤ 4 weeks prior to study entry Biologic therapy ≤ 4 weeks prior to study entry
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Oral Cavity Cancer 18 years of age or older Able to provide written informed consent to participate Diagnosis of head and neck malignancy involving an oral cavity site without previous treatment Current treatment plan includes surgical intervention English speaking  Previous treatment for malignancy in the head and neck region Significant preexisting facial disfigurement from a previous trauma or congenital defect Diagnosis of a serious mental illness involving formal thought disorder (e.g., Schizophrenia) documented in medical record
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Lung Cancer Histological or cytological diagnosis of non-small cell lung cancer Malignant pleural effusion proven by cytological examination Patient must have stage IIIB or IV disease with malignant pleural effusion We plan to recruit 16 patients who have smoked cigarettes of at least 20 pack per year, 16 patients who do not smoke but have been exposed to second hand smoking by living with a person who has smoked 20 pack per year cigarette in the same household and 16 patients who are non-smokers (never smoked) and no second hand smoking exposure in the same household. The accrual will be stopped once the number of patients is reached in each group ECOG PS 0, 1 or 2 Measurable disease (in addition to malignant pleural effusion) No prior chemotherapy for metastatic or recurrent disease. Patient may have surgery or radiation or combined chemoradiation, or neoadjuvant chemotherapy at primary diagnosis. This kind of chemotherapy will not be counted as patient has had prior chemotherapy for metastatic or recurrent NSCLC WBC > 3500/uL and ANC > 2,000/uL, platelet > 100,000/uL AST/ALT < 3 X UNL, bilirubin < 1.5 mg/dL ( or < 35 uM), creatinine < 1.5 mg/dL (or < 125uM for men and 90uM for women) Age > 18 No history of congestive heart failure, myocardial infarction or life-threatening arrthymia (such as ventricular tachycardia, supraventricular tachycardia, brachycardia < 40/min or atrial fibrillation or flutter with ventricular rate > 150/min) within 6 months of entry  ECOG performance status 3 or worse Any prior chemotherapy regimen for metastatic or recurrent diseases No measurable disease, even after drainage of pleural effusion ANC < 1,999/uL or Bilirubin > 1.5 mg/dL (or > 35uM) Plt < 100,000/uL or ALT/AST > 3 x UNL Creatinine > 1.5mg/dL (or > 125uM) Patient has history of congestive heart failure, myocardial infarction or life-threatening arrthymia (such as ventricular tachycardia, supraventricular tachycardia, atrial fibrillation/flutter with ventricular rate > 150/min or bradycardia < 40/min) within 6 months before entry Prior history of breast cancer or ovarian cancer in female patients or any cancer except cured cervical carcinoma in-situ or skin cancer Fasting blood sugar > 200 mg/dL (> 14uM) except in patients on dexamethasone for brain metastases
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 21.0-79.0,  Head and Neck Neoplasms The target population for this study is 125 patients with stages III or IV squamous cell lesions of the oral cavity, oropharynx, pharynx or larynx, or unknown primary  No patient will have had prior treatment for head and neck cancer or any otolaryngologic or neurologic disorder affecting swallow and no preexisting swallowing disorder
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 16.0-65.0,  Pharyngitis Patients having a sore throat with acute viral pharyngitis. 2. Female and male ambulant patients between the ages of 18 and 65. 3. The throat pain intensity is rated at least severe on the VRS (PI). 4. Written Informed Consent is given by the patient. 5. Compliance by the patient seems guaranteed Patients with symptoms of primarily bacterial pharyngitis or bacterial secondary infection (clinical findings; inter alia assessment of exudate) First indication of symptoms of acute pharyngitis (e.g., sore throat) occurred more than 3 days ago already Counting of white blood cell in blood routine examination exceeds 10?109/L Patients who suffered from acute viral or bacterial pharyngitis in the past 4 weeks Broncho-motor disorders or concomitant diseases with relatively large quantities of secretion (danger of secretion blockage) Known hypersensitivity to Ambroxol or to auxiliary substances contained in the tablet Previous and/or existing tumour condition Pregnancy and/or breast-feeding Alcohol, and/or drug abuse
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Smoking Cessation Patient seeking routine dental care at NYU College of Dentistry and meets medical clearance for routine care Active smokers (active smoking as self-reported regular use of at least 10 cigarettes per day) Able to provide a telephone number or collateral contact information where they can be reached over the subsequent 12 months Fluent in English or Spanish  History of mouth or throat cancer
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Head and Neck Cancer Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx No histologic diagnosis other than squamous cell carcinoma A primary site must be identified Must have locoregionally confined stage III (excluding T1-2, N1) or stage IV disease No evidence of nodal disease below the clavicles or distant hematogenous metastases (M0) No stage IVC disease (stage IVB disease allowed) Deemed appropriate for definitive non-operative management with curative intent Resectable disease is not required No primary cancer of the nasopharynx, paranasal sinus, or salivary gland ECOG performance status 0-1  Patients with primary cancers of the nasopharynx, paranasal sinus or salivary gland are ineligible Patients with unstable or uncontrolled angina, clinically apparent jaundice, or active infection are ineligible Patients with a history of any other malignancy (except squamous or basal cell skin cancer or cervical carcinoma in-situ) are ineligible, unless the patient has been continuously disease-free for at least 5 years Patients with any histologic diagnosis other than squamous cell carcinoma are ineligible Patients who might be a poor-compliance risk are ineligible Pregnant or breastfeeding women are ineligible. Women/men of reproductive potential must be willing to practice acceptable methods of birth control to prevent pregnancy
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Esophageal Cancer Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or rectum Planning to receive neoadjuvant treatment, including radiotherapy or chemoradiotherapy Not pregnant or nursing No blood disorder Not deprived of freedom or protected by law See Disease Characteristics
Patient description: A 52-year-old African American man with a history of heavy smoking and drinking, describes progressive dysphagia that began several months ago. He first noticed difficulty swallowing meat. His trouble swallowing then progressed to include other solid foods, soft foods, and then liquids. He is able to locate the point where food is obstructed at the lower end of his sternum. He has lost a total of 25 pounds.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pharyngitis Included patients had moderate to severe pain, as measured by the Sore Throat Pain Intensity Scale (STPIS) on swallowing ≥66 mm on a 100-mm visual analogue scale (VAS) and a minimum of 4 points on the 10-point Tonsillo-Pharyngitis Score (TPS) but who were not coughing or experiencing any evidence of mouth-breathing  Patients who used throat lozenges, throat spray, cough drops or menthol-containing products within 2 hours, short-acting analgesics/antipyretics (eg, ibuprofen) or any form of cold medication within 8 hours, antibiotics for acute disease within 24 hours of first dose of study medication, or presumed diagnosis of infectious mononucleosis, known allergy or hypersensitivity to NSAIDs, COX-2 specific inhibitors, sulfonamides, or acetaminophen were excluded